JC05 Rec'd PCTPTO 1 3 JUL 2007 PC+

UL 1 3 2001 IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

(ASHMIRI et al.

Examiner:

Unknown

Serial No BADE 09/830748

Group Art Unit:

Unknown

Filed:

30 April 2001

Docket:

11613.32USWO

Due Date:

13 July 2001

Title:

VARIANTS OF HUMANIZED ANTI-CARCINOMA MONOCLONAL ANTIBODY CC49

CERTIFICATE UNDER 37 CFR 1.10

'Express Mail' mailing label number: EL669942685US

Date of Deposit: 13 July 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service 'Express Mail Post Office To Addressee' service under 37 CFR 1.10 on the date indicated above and is addressed to the Commissioner of Patents and

Trademarks, Washington, D.C. 20231.

Omesh Singh

MISSING REQUIREMENTS

Commissioner for Patents Washington, D.C. 20231

Sir:

We are transmitting herewith the attached:

Computer readable form of sequence listing. Applicants state that the paper copy form of the sequence listing section of the present application, and the computer readable form submitted herewith, are the same.

Other: Form PCT/DO/EO/917, Form PCT/DO/EO/920, Submission of Computer Readable Sequence Listing

Return postcard

Please consider this a PETITION FOR EXTENSION OF TIME for a sufficient number of months to enter these papers, if appropriate. Please charge any additional fees or credit overphyment to Deposit Account No. 13-2725. A duplicate of this sheet is enclosed.

MERCHANT & GOULD P.C. P.O. Box 2903, Minneapolis, MN 55402-0903.

612.332.5300

Name: Melissa Jean Pytel

Reg. No.: 41,512 MJP/kjr

23552

PATENT TRADEMARK OFFICE

Commissioner for Patents, Box PCT United States Patent and Trademark Office Washington, D.C. 20231

U.S. APPLICATION NO.	FIRST NAMED APPLICANT		ATTY, DOCKET NO.	
09/830748	KASHMIRI	S	11613.32USWO	
		INTERNATIONAL APPLICATION NO.		
MELISSA JEAN PYTEL MERCHANT & GOULD		PCT/	PCT/US99/25552	
P O BOX 2903		I.A. FILING DATE	E PRIORITY DATE	
MINNEAPOLIS, MN 55402 0903		29 OCT 99	31 OCT 98	
		DATE MAILE	. 13 JUN 2001	

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

required by 37 CFR 1.821(e). A copy of the "Sequence Listing" in compute content of the computer readable form, how 37 CFR 1.822 and/or 1.832, as indicated or Sequence Listing." The computer readable form that has been to the computer readable.	nce Listing" as a separate part of the as required by 37 CFR 1.821(c). Iter readable format has not been submitted as ter readable form has been submitted. The rever, does not comply with the requirements of the attached marked-up copy of the "Raw filed with this application has been found to be the attached CRF Diskette Problem Report. A submitted as required by 37 CFR 1.825(d). Indence Listing" is not the same as the
Other:	Listing as required by 37 CFR 1.021(c).
amendment directing its entry into the spec	act disc of the "Sequence Listing," as well as an ification. If compact disc and the computer readable form to no new matter, as required by 37 CFR
FOR QUESTIONS REGARDING COMPLIANCE W CALL: (703) 308-4216, for Rules interpretation, (703) 308-4212, for CRF submission help, (703) 287-0200, for PatentIn software help.	ITH THESE REQUIREMENTS, PLEASE .
	Barbara A. Campbell Telephone: 703-305-3631

FORM PCT/DO/EO/920 (March 2001)

